- Enovis Companion Animal Health has launched the CT-RevitL™ laser therapy system in the U.S. veterinary market.
- The platform features COMPASS™, an intelligent treatment guidance system designed to improve dosing consistency and reduce treatment variability.
- CT-RevitL™ is intended for use in managing pain, reducing inflammation, promoting tissue healing, and supporting post-operative recovery.
- Enovis says the system builds on more than 150 published studies involving photobiomodulation (PBM) therapy.
- The company expects international availability to follow after the U.S. launch.
Enovis Companion Animal Health has introduced CT-RevitL™, its latest photobiomodulation (PBM) laser therapy system, expanding its portfolio of non-pharmaceutical treatment technologies for veterinary practices.
Available in the United States beginning July 13, the new system is designed to support the treatment of musculoskeletal and soft tissue conditions by delivering laser therapy for pain management, inflammation reduction, tissue healing, and post-operative recovery.
Intelligent treatment guidance
A key feature of CT-RevitL™ is COMPASS™, Enovis’ intelligent treatment guidance technology, which is designed to deliver calibrated laser dosing and reduce variability between users. According to the company, the system is intended to simplify treatment delivery while promoting more consistent clinical application across veterinary teams.
Enovis said the platform was developed to improve workflow efficiency and make high-powered laser therapy easier to integrate into routine clinical practice.
Supporting practice growth
In addition to its clinical applications, the company said CT-RevitL™ is designed to help practices expand non-drug treatment offerings and establish repeatable therapy protocols that can support recurring patient visits.
The launch marks the latest addition to Enovis’ Companion Animal Health portfolio, with international rollout planned following the initial U.S. introduction.
Information sourced from Enovis Corporation’s press release.
